BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 728284)

  • 1. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
    Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
    Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.
    Longmore J; Berry JL; Szabadi E; Bradshaw CM
    Eur J Clin Pharmacol; 1990; 39(3):305-9. PubMed ID: 2257872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of the disopyramide concentration-effect relationship.
    Whiting B; Holford NH; Sheiner LB
    Br J Clin Pharmacol; 1980 Jan; 9(1):67-75. PubMed ID: 7356895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
    De Graeve J; Kremers P; Gielen JE
    Therapie; 1977; 32(2):195-204. PubMed ID: 898127
    [No Abstract]   [Full Text] [Related]  

  • 8. The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
    Haskins NJ; Waddell KA; Ford GC; Spalton PN; Walls CM; Forrest TJ; Palmer RF
    Biomed Mass Spectrom; 1980 Feb; 7(2):80-3. PubMed ID: 7407335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disopyramide pharmacokinetics during recovery from myocardial infarction.
    Bryson SM; Cairns CJ; Whiting B
    Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
    Karim A; Kook C; Campion J; Doherty M
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
    Ashford JJ; Carmichael D; Kidner PH
    Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
    [No Abstract]   [Full Text] [Related]  

  • 16. Disopyramide pharmacokinetics and bioavailability.
    Dubetz DK; Brown NN; Hooper WD; Eadie MJ; Tyrer JH
    Br J Clin Pharmacol; 1978 Sep; 6(3):279-81. PubMed ID: 687507
    [No Abstract]   [Full Text] [Related]  

  • 17. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
    Cook CS; Karim A; Sollman P
    Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.